| First Author | Del Reino P | Year | 2014 |
| Journal | Cancer Res | Volume | 74 |
| Issue | 21 | Pages | 6150-60 |
| PubMed ID | 25217523 | Mgi Jnum | J:217203 |
| Mgi Id | MGI:5613307 | Doi | 10.1158/0008-5472.CAN-14-0870 |
| Citation | Del Reino P, et al. (2014) Pro-oncogenic role of alternative p38 mitogen-activated protein kinases p38gamma and p38delta, linking inflammation and cancer in colitis-associated colon cancer. Cancer Res 74(21):6150-60 |
| abstractText | p38 MAPK signaling has been implicated in the regulation of processes leading to cancer development and progression. Chronic inflammation is a known risk factor for tumorigenesis, yet the precise mechanism of this association remains largely unknown. The related p38alphaMAPK (MAPK14) proteins p38gamma (MAPK12) and p38delta (MAPK13) were recently shown to modulate the immune response, although their role in tumorigenesis remains controversial and their function in inflammation-associated cancer has not been studied. We analyzed the role of p38gamma and p38delta in colon cancer associated to colitis using the azoxymethane/dextran sodium sulphate (AOM/DSS) colitis-associated colon cancer model in wild-type (WT), p38gamma-, p38delta-, and p38gamma/delta-deficient (p38gamma/delta(-/-)) mice. We found that p38gamma/delta deficiency significantly decreased tumor formation, in parallel with a decrease in proinflammatory cytokine and chemokine production. Analysis of leukocyte populations in p38gamma/delta(-/-) mouse colon showed less macrophage and neutrophil recruitment than in WT mice. Furthermore, WT chimeric mice with transplanted p38gamma/delta(-/-) bone marrow had less tumors than WT mice transplanted with WT bone marrow, whereas tumor number was significantly increased in p38gamma/delta(-/-) chimeric mice with WT bone marrow compared with p38gamma/delta(-/-) mice transplanted with p38gamma/delta(-/-) bone marrow. Together, our results establish that p38gamma and p38delta are central to colitis-associated colon cancer formation through regulation of hematopoietic cell response to injury, and validate p38gamma and p38delta as potential targets for cancer therapy. |
